You are here: Industry Insights > INOVIO

News List

INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S. prnewswire
November 10, 2021
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer...
INOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 With Regulatory Authorization from India prnewswire
November 04, 2021
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases, and help treat cancer, and HPV-associated diseases...
INOVIO Announces Collaboration with Colombia; Memorandum of Understanding Focuses on Protecting Against COVID-19 and Supporting Broader Health Preparedness Initiatives prnewswire
October 22, 2021
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases...
INOVIO Announces Online Preprint Publication of Homologous Boosting Data for its COVID-19 DNA Vaccine Candidate, INO-4800 prnewswire
October 13, 2021
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases...
INOVIO Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include Colombia following Regulatory Authorization prnewswire
October 12, 2021
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases...
INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico prnewswire
September 28, 2021
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases
INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800 prnewswire
August 27, 2021
INOVIO today announced that it has received regulatory authorization from Brazil's ANVISA (Agência Nacional de Vigilância Sanitária), the national health regulatory agency of Brazil, to initiate the global Phase 3 segment of its Phase 2/3 trial.
Inovio to commence Covid-19 vaccine prime-boost trials in China pharmaceutical-technology
August 11, 2021
Inovio has obtained regulatory approval from China’s Center for Drug Evaluation of the National Medical Products Administration to conduct two clinical trials of heterologous prime-boosting with its Covid-19 vaccine candidate, INO-4800.
Inovio focused on launching global COVID-19 vaccine trial next month - CEO firstwordpharma
August 10, 2021
Inovio Pharmaceuticals CEO Joseph Kim says the company is focused on launching a late-stage trial of its COVID-19 vaccine candidate INO-4800 next month, with the drug developer expecting data in the first half of 2022, as reported in Yahoo!News.
INOVIO Expands Partnership with Advaccine to Conduct Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate americanpharmaceuticalreview
June 10, 2021
INOVIO, a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, announced an expansion of its partnership with Advaccine ...

Previous page 1 2 3 4 5 Next page